New Lintuzumab Combination Therapy for AML Safe, Potentially Effective


A Phase I study reports on the safety and potential efficacy of lintuzumab Ac225 plus CLAG-M for relapsed/refractory acute myeloid leukemia.

Sameem Abedin, MD

Sameem Abedin, MD

A study presented at the American Society of Hematology (ASH) 2020 Annual Meeting reported an acceptable safety profile for lintuzumab Ac225 plus CLAG-M, a combination therapy for relapsed/refractory acute myeloid leukemia (AML).

Previous research has shown upfront therapy of lintuzumab Ac225, a radiolabeled anti-CD33 antibody, to be efficacious for unfit AML without significant non-hematological toxicity.

Sameem Abedin, MD, Division of Hematology/Oncology, Medical College of Wisconsin, and colleagues thus conducted the first study to combine radioimmunotherapy with salvage chemotherapy in patients with AML.

The team enrolled medically fit patients (n = 15), all of whom were ≥18 years of age. The median age was 61 years. Further, less than half of the patients received venetoclax/HMA, while more than half had previously received hematopoietic cell transplantation (HCT).

Therapy induction consisted of 300 mcg/d of G-CSF given from days 1-6; 5 mg/m2 of cladribine given from days 2-6; and 10 mg/m2 of mitoxantrone given from days 2-4.

Lintuzumab Ac225 was then administered as a single dose on days 7, 8, or 9. Patients were divided into 3 dosage level cohorts—0.25uCi/kg (Cohort 1, n = 3), 0.50uCi/kg (Cohort 2, n = 9), or 0.75uCi/kg (Cohort 3, n =3).

Reported adverse events were Grade 3 or higher and were irrespective of causality. These included febrile neutropenia (n = 12), infection (n = 8), and maculopapular rash (n = 3). Furthermore, each patient experienced QTc prolongation and tumor lysis syndrome.

Of the 15 patients, 10 experienced a complete remission or complete remission with incomplete count recovery. This total amount remained even after excluding patients who had previously received >3 lines of therapy.

In cohort 1, 1 patient achieved complete remission. As for cohort 2, 3 achieved complete remission, 2 achieved complete remission with incomplete platelet recovery, and 1 achieved complete remission with incomplete count recovery.

And finally, in cohort 3, all 3 patients achieved remission—1 achieved complete remission and 2 achieved complete remission with incomplete platelet recovery.

Of the 10 total with either complete remission or complete remission with incomplete count recovery, 7 achieved minimal residual disease (MRD) negativity by flow.

Abedin and colleagues also reported that all patients who were independent for platelet transfusions pre-treatment recovered platelets.

“Overall, median time to ANC recovery ≥500 was 33 days, and median time to platelet recovery ≥50k was 35 days,” they wrote. 

Further, 6 patients proceeded to allogenic HCT following therapy.

Because of the observed acceptable safety at 0.75uCi/kg, the team will proceed with studying a 4th dosage cohort at 1.0uCi/kg.

“Overall, this regimen represents a safe and potentially effective therapy for medically fit RR-AML patients, particularly as a bridge to allogeneic HCT,” they concluded

The study, “A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML,” was presented at ASH 2020.

Related Videos
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Signs and Symptoms of Connective Tissue Disease
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
© 2024 MJH Life Sciences

All rights reserved.